To view this email as a web page, click here.

 
Dermatology Times
TLR9 agonist for metastatic melanoma?
The combination of pembrolizumab and a TLR9 agonist known as SD-101 showed promising activity in patients with unresectable or metastatic melanoma.
ADVERTISEMENT
 
Dermatology Times
PET-CTs may be less beneficial for melanoma
Stage II melanoma patients don't always benefit from staging PET-CT, according to Duke University Medical Center researchers.
ADVERTISEMENT
 
Surgeons defer procedures in early pregnancy
image description here Prompt management of skin cancer lesions is stressed for pregnant patients in a recent article in the Journal of the American Academy of Dermatology, but whether it's applied in clinical practice is unknown.
 
Lifestyle Features for Physicians
 
Dermatology Times cover
YouTube—the holiday helper
 
Don't end up like Old Man Winter
 
Don't let the winter blues dampen your holiday
 
From Our Latest Issue
 
Dermatology Times cover
High efficacy shown in self-inject PsO biologic
 
Inadequately controlled atopic dermatitis
 
Individualized biologic therapy
 
ADVERTISEMENT
Three areas for body-sculpting, one treatment.
In this podcast, Dr. Amy Taub discusses strategies dermatology practices can use to incorporate noninvasive body sculpting solutions, such as the truSculpt iD, into their daily workflow. Listen to the podcast now.
 
JOB OPPORTUNITIES
 
 
ADVERTISEMENT
The Cosmetic Professional's Guide to Patient Financing
Would you like to grow your revenue while saving thousands in provider fees? Download the Ultimate Guide to Patient Financing to learn how! Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.